Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · IEX Real-Time Price · USD
2.220
+0.070 (3.26%)
Jul 22, 2024, 10:17 AM EDT - Market open
Eterna Therapeutics Employees
Eterna Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
$14,375
Profits / Employee
-$2,864,375
Market Cap
11.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | -1 | -10.00% |
| Dec 31, 2021 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ontrak | 104 |
| Check-Cap | 85 |
| RedHill Biopharma | 53 |
| Calidi Biotherapeutics | 41 |
| Vaccinex | 40 |
| Lumos Pharma | 33 |
| Imunon | 33 |
| BioRestorative Therapies | 11 |
ERNA News
- 2 months ago - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs - GlobeNewsWire
- 2 months ago - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewsWire
- 5 months ago - Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - GlobeNewsWire
- 7 months ago - Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - GlobeNewsWire
- 7 months ago - Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - GlobeNewsWire
- 7 months ago - Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewsWire
- 9 months ago - Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors - GlobeNewsWire
- 11 months ago - Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics - GlobeNewsWire